Fuji Chemical presents an innovative dibasic calcium phosphate anhydrous (DCPA) for direct compression tabletting. Compared to conventional DCPA and DCPD, Fujicalin® delivers improved benefits largely because of the unique manufacturing process. During synthesis, the primary crystal growth is restricted to sub-micron size. After that, spray-drying step combines the sub-micron crystals which form spherical and smooth granules (mean particle diameter of 112 mm).Features that make Fujicalin Unique
Neutral pH, low hygroscopicity, high compactability leads to tablet volume reduction, and dissolves quickly in gastric acid.
Conforms to USP/NF and JP under dibasic calcium phosphate anhydrous and Ph. Eur under calcium hydrogen phosphate anhydrous.
Pharmaceutical and food applications involving direct compression. Fujicalin® may be used to replace existing excipients or used in part to synergize with other components.